CiMaas has been granted patent on DC maturation technology

CiMaas, a biotech company developing innovative cellular immunotherapy, announced the grant of a European Patent on its Dendritic Cells maturation technology, an essential part of its Dendritic Cell Vaccine Product. 

On March 14, The European Patent Office granted patent EP2847321 entitled " METHOD FOR THE IN VITRO MATURATION OF DENDRITIC CELLS”. The patent claims cover a proprietary maturation and stimulation technology activating DC to stimulate T helper cells, Natural Killer Cells leading to optimal T-killer cell activation against tumor cells. CiMaas currently develops DC-Xcite and has started preparations to investigate the therapeutic vaccine in a phase I/II clinical trial in lung cancer patients. The grant of this patent further strengthens CiMaas’ IP position and provides an important basis to advance its innovative DC vaccine technology and achieving a better cure for cancer in the future” says Gerard Bos, CEO of CiMaas.
 
About CiMaas
CiMaas aims to develop cellular immunotherapy for specific groups of cancer patients. The company develops unique products based on cells and antibodies from the immune system. CiMaas BV is a spin-off of Maastricht University/Maastricht University Medical Centre+ (UM/Maastricht UMC+).